Bristol-Myers Squibb’s Opdivo Gains Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer
The US drugs safety regulator has fast-tracked the approval of Opdivo (nivolumab) to extend its current use to a new group of patients with advanced lung cancer.